Marshall Wace, LLP Kinnate Biopharma Inc. Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.24 - $2.66 $85,968 - $102,088	-38,379 Reduced 19.74%	156,089 $415,000
Q4 2023 Feb 14, 2024	BUY	$1.07 - $2.5 $118,042 - $275,800	110,320 Added 131.1%	194,468 $460,000
Q3 2023 Nov 14, 2023	SELL	$1.38 - $3.31 $33,536 - $80,439	-24,302 Reduced 22.41%	84,148 $117,000
Q2 2023 Aug 14, 2023	BUY	$2.33 - $6.84 $252,688 - $741,798	108,450 New	108,450 $328,000
Q4 2022 Feb 14, 2023	BUY	$5.26 - $12.19 $18,367 - $42,567	3,492 Added 30.49%	14,944 $91,000
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $112,916 - $180,483	11,452 New	11,452 $137,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.